Ingxelo yeTyala leMpendulo epheleleyo yexesha elide kwiHepatocellular Carcinoma kwiGPC3 CAR T Cells (CT011)

I-CT011 yimveliso ye-GPC3 CAR T-cell ekhethiweyo yonyango lwe-hepatocellular carcinoma (HCC). I-CT011 yafumana imvume ye-IND kwi-NMPA ngo-2019 yokunyanga izigulana ezine-GPC3-positive solid tumor eyayiyeyona mvume yokuqala yaseTshayina yonyango lwe-CAR T-cell nxamnye nee-solid tumors.

Nge-18 ka-Agasti 2022, iCARsgen Therapeutics ibhengeza ukuba ingxelo yetyala, enesihloko esithi “Impendulo Epheleleyo Yexesha Elide Ye-Advanced Hepatocellular Carcinoma kwi-Glypican-3 Specific Chimeric Antigen Receptor T-Cells kunye neSorafenib, Ingxelo yetyala”, ipapashwe kwiFrontiers in Immunology.

Ityala libonise isigulana esiyindoda saseAsia esineminyaka engama-60 ubudala esine-HCC enxulumene ne-hepatitis B virus (HBV) esatyandwa ngoMeyi 2018. Ngo-Agasti 2018, ukuphinda kuvele umhlaza wesibindi kunye ne-metastasis yemiphunga kwenzeka emva kotyando, waza emva koko wafumana i-transarterial chemoembolization (TACE) ukunyanga izilonda zesibindi kunye ne-interventional ablation ukunyanga i-metastases yemiphunga. Emva kweenyanga ezimbini, waqhubela phambili waza wabhaliswa kwisilingo seklinikhi. Emva kokubhaliswa, isigulana senziwa i-leukapheresis yokwenziwa kweeseli ze-CAR-GPC3 T. Emva kweentsuku ezisixhenxe emva kwe-leukapheresis, isigulana saqala ukufumana i-400 mg ye-sorafenib kabini ngemini. Isigulana safumana imijikelo emi-4 yonyango lweeseli ze-CAR-GPC3 T (CT011) kwaye umjikelo ngamnye wahlulwe waba zii-infusions ezimbini. Ngaphambi komjikelo ngamnye wonyango lwe-CT011, kwenziwa i-lymphodepletion. I-4×10 iyonke.⁹Iiseli ze-T ze-CAR-GPC3 zifakwe.

Unyango oludibeneyo lwe-CT011 kunye ne-sorafenib lwalunyamezeleka kakuhle. Esi sigulana sifumene iimpendulo ezingaphelelanga (PR) ukusuka kwinyanga yesi-3 saza safumana i-CR kwinyanga ye-12 emva komjikelo wokuqala wokufakwa kwe-CT011. Ithumba alizange liqhubeke ixesha elingaphezu kweenyanga ezingama-36 kwaye lagcina imeko ye-CR ixesha elingaphezulu kweenyanga ezingama-24 emva kokufakwa kokuqala.

Ngokolwazi lwethu, le yimeko yokuqala exeliweyo nge-CR emva konyango oludibeneyo lweeseli ze-CAR T kunye nee-tyrosine kinase inhibitors. Iziphumo zeklinikhi zibonise ukuba unyango oludibeneyo lwe-GPC3 CAR T-cell kunye ne-Sorafenib lunokuba yindlela entsha ethembisayo kwizigulane ze-GPC3+ eziphambili ze-HCC.

Okwangoku, kukho ezinye iimvavanyo ezininzi zeklinikhi ze-CAR-T eTshayina, kwaye zikhangela izigulane. Ukuze ufumane iingcebiso ngamayeza amatsha kunye netekhnoloji, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.

Inombolo yefowuni: 4008803716

Email：myimmnet@163.com